Disease

Womenhealthsecret.com

TREATING DEPRESSION MAY PROTECT AGAINST INSULIN RESISTANCE IN TYPE 2 DIABETES PATIENTS

US researchers found that treating depression may protect against insulin resistance observed in depression in patients at risk of type 2 diabetes. The study was conducted by Dr Julie Wagner of the University of Connecticut Health Center, and colleagues, and was presented at the 69th Scientific Sessions of the American Diabetes Association that took place in New Orleans, Louisiana from 5 to 9 June.


TYPE 2 DIABETES: PREVENTION OR DELAY WITH LIFESTYLE INTERVENTION OR METFORMIN LASTING AT LEAST 10 YEARS

An article published Online First and in a future edition of The Lancet reports that prevention or delay of type 2 diabetes with lifestyle intervention or metformin can persist for at least ten years. The article is the work of Dr. William C. Knowler of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases and colleagues from the Diabetes Prevention Program Research Group.


VOGLIBOSE REDUCES OCCURRENCE OF TYPE 2 DIABETES IN HIGH RISK JAPANESE PEOPLE

Together with lifestyle changes, the drug Voglibose reduces the progress of type 2 diabetes in high-risk Japanese people. Professor Ryuzo Kawamori, from the Juntendo University School of Medicine, in Tokyo, Japan, and his colleagues report their findings in an article published Online First and in a future edition of The Lancet.


INFLAMMATORY FACTORS AND DIABETIC MACULAR EDEMA HIGHLIGHTED IN OPHTHALMOLOGY JAN. 2009

With a new study from the Centers for Disease Control and Prevention predicting that diabetic retinopathy will triple from 5.5 million in 2005 to 16 million in 2050, improved treatments are urgently needed for this leading cause of blindness in working-age people. The CDC study is the latest indicator of a world-wide diabetes epidemic that is motivating ophthalmic research around the globe.


FDA APPROVES FIRST GOUT DRUG IN 40 YEARS

The US Food and Drug Administration has given marketing approval to a new drug that lowers levels of uric acid in the blood of patients with gout: the current treatment for the condition was developed over 40 years ago. The new drug is called ULORIC (generic name febuxostat) and Takeda Pharmaceuticals North America is the sole developer and marketer of the product in the US.


SWINE FLU 2,371 OFFICIALLY CONFIRMED CASES IN 24 COUNTRIES, INCLUDING 42 DEATHS IN MEXICO AND 2 DEATHS IN THE USA

According to the World Health Organization (WHO), 2,371 humans have been officially infected with the influenza A (H1N1) virus - the so-called swine flu virus - with 42 deaths in Mexico and 2 deaths in the United States. Below is a list of countries, with confirmed human case totals, and deaths. Mexico - 1,112 confirmed cases, 42 deaths USA - 896 confirmed cases, 2 deaths Canada - 201 Spain - 81 United Kingdom - 32 Germany - 10 France - 5 Italy - 5 New Zealand - 5 South Korea - 3 El Salvador - 2 Netherlands - 2 Austria - 1 China/Hong Kong - 1 Colombia - 1 Costa Rica - 1 Denmark - 1 Guatemala - 1 Ireland - 1 Israel - 1 Poland - 1 Portugal - 1 Sweden - 1 Switzerland - 1 WHO says travel restrictions related to the current outbreak of swine flu are not recommended.


SWINE FLU: TOP 20 QUESTIONS AND ANSWERS

Rumors are rife as the swine flu theme evolves. Here are twenty questions answered by Charles Ericsson M.D., Prof. Internal Medicine, Director of Travel Medicine, University of Texas Medical School, and Robert Emery DrPH, VP Safety, Health, Environment & Risk Management, UT Health Science Center, and Associate Prof.


FDA APPROVES KOMBIGLYZE XR TABLETS FOR TYPE 2 DIABETES MELLITUS IN ADULTS

Kombiglyze XR tablets for type 2 diabetes treatment in adults has been approved by the Food and Drug Administration (FDA). It is a once daily saxagliptin (Onglyza) and extended-release metformin diabetes medication. According to AstraZeneca and Bristol-Myers Squibb "Kombiglyze XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across glycosylated haemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG).


NEARLY 30% OF AMERICANS LIKELY TO HAVE DIABETES BY 2050

The incidence of diabetes, mostly diabetes Type 2, is expected to rise from 8 newly diagnosed cases per thousand in 2008 to approximately 15 by the year 2050, researchers from the CDC (Centers for Disease Control and Prevention) and Emory University report in an article published in Popular Health Metrics.


TYPE 1 DIABETES REVERSED IN MICE

Using gene therapy, researchers in the US managed to reverse Type 1 diabetes in laboratory mice, raising hope that a "cure" for the disease might be developed using this approach. However, only about 50 per cent of the treated mice responded to the therapy, so there is still a lot of work to do before such a method can be trialled as a potential treatment.


HEALTHY BABY BORN FROM 20-YEAR OLD EMBRYO

A 42-year old woman in the US has given birth to a healthy baby after being implanted with an embryo that was frozen for nearly 20 years. The baby's birth mother had been having fertility treatment for 10 years before she received the donated embryo, created by a couple who underwent IVF treatment 20 years ago.


CONCERN AS 10 PEOPLE DIE OF SWINE FLU (H1N1) IN UK IN SIX WEEKS

Fear of another H1N1 influenza epidemic, also known as swine flu, has been expressed by some health experts in the UK after the country's Health Protection Agency (HPA) confirmed that ten people have died after becoming infected over the last six weeks. The HPA confirms that the H1N1 virus is circulating again this winter.


H1N1 2009 SWINE FLU COMPLICATIONS NO WORSE THAN SEASONAL FLU, US

A US study of flu cases in adults and children living in Wisconsin concluded that the risk of serious complications from 2009 H1N1 swine flu was no higher than the risk of serious complications from recent seasonal flu strains. You can read about the study in the 8 September issue of the Journal of the American Medical Association, JAMA.


HATE TAKING ALLERGY DRUGS? GET BETTER WITH IMMUNOTHERAPY: TESTED FOR 100 YEARS -NEW ADVANCEMENTS

Antihistamines and nasal steroids offer good short-term options for people with mild allergy, but allergy immunotherapy, better known as "allergy shots," is a preferred method for achieving long term remission of more bothersome allergy symptoms. Allergists mark the 100th anniversary of immunotherapy and present the latest advances at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting in Phoenix, Nov.


NIH-FUNDED STUDY: NEARLY 3 OF 100 AMERICANS HAVE A FOOD ALLERGY

An estimated 2.5 percent of Americans - 7.5 million people - have at least one food allergy and young black children with asthma appear to be at the highest risk, according to findings from what is believed to be the largest food allergy study to date. The research was conducted by investigators at Johns Hopkins Children's Center, the National Institutes of Health and other institutions.


PEANUT ALLERGY MISDIAGNOSED IN 2 OUT OF 3 CASES

Allergy to peanuts is one of the most common and feared food allergies. Due to its infamously severe reactions, peanut allergy has always been associated with a deep anxiety, especially in parents of peanut allergic children. Now, a recent study makes it possible to give a majority of these parents some reassuring news.


PEANUT ALLERGY MISDIAGNOSED IN 2 OUT OF 3 CASES

Allergy to peanuts is one of the most common and feared food allergies. Due to its infamously severe reactions, peanut allergy has always been associated with a deep anxiety, especially in parents of peanut allergic children. Now, a recent study makes it possible to give a majority of these parents some reassuring news.


RATE OF PEANUT ALLERGIES IN CHILDREN MORE THAN TRIPLED BETWEEN 1997 AND 2008

Results of a nationwide telephone survey have shown that the rate of peanut allergies in children more than tripled from 1997 to 2008. The data are reported in the May 12 issue of the Journal of Allergy and Clinical Immunology. Led by Scott H. Sicherer, MD, Professor of Pediatrics, Jaffe Food Allergy Institute at Mount Sinai School of Medicine, researchers surveyed a total of 5,300 households, representing 13,534 individuals in 2008, a response rate of 42 percent.


DEMENTIA TO COST THE WORLD $601 BILLION THIS YEAR, 1% OF GLOBAL GDP

Alzheimer's disease and other dementias are having an enormous and growing impact on the world economy, and will surpass $601 billion by the end of this year; over 1% of global GDP (Gross Domestic Product), says a new report " World Alzheimer Report 2010" - published by Alzheimer's Disease International.